BioCentury on BioBusiness,
Strategy
Genomic pioneers gone; how next-generation players will solve big data
Big data: Then and now
By Erin McCallister
Senior Writer
Published on
Monday, September 24, 2012
The early genomics pioneers
awakened the biopharma industry to the value of capturing and using data to
drive drug development. But both the pioneers and those who have followed agree
the industry still has far to go to harness the power of big data.
Human Genome Sciences Inc. was the last of the independent
first-generation genomics companies. Having raised $3.9 billion since its
inception in 1992, it was acquired last month by GlaxoSmithKline
plc for $2.9 billion. HGS and its peers believed analyzing human
sequence data would unleash a wave of new cures. But it turned out everyone was
naïve about the complex nature of diseases, and the fount of cures never
materialized.
113
words displayed of
3254
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]